LuCE aims to raise awareness about inequities regarding the access to lung cancer treatment and care in Europe. Moreover, it advocates European policies that will lead to improvements in lung cancer prevention, early detection, treatment and care.
Lung Cancer Europe provides a European platform for national lung cancer patient advocacy groups and supports the establishment of those groups in countries where such groups do not yet exist. Our member organisations and associate members come from all over Europe.
Lung cancer is literally the biggest cancer killer worldwide – causing more deaths than breast and prostate cancer put together all over the world. Read more about our diagnosis, types and stages of lung cancer, treatments and clinical trials, but also how to cope with lung cancer.
The responses are for informational use only―they don’t substitute the medical advice. If you have specific questions about your own situation, please consult your treating physician.
What is COVID-19? COVID-19 is an illness caused by a novel (new) coronavirus that was identified in December 2019. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. Human coronaviruses are a large family of viruses. They are common and often cause mild illnesses, such as the common cold. But they can also cause more serious illnesses. […]
In depth webinar held on 26th of February 2020 with Kate Morgan, from Myeloma Patients Europe about the role of the European Medicines Agency (EMA) and how patients and patient advocates can be involved in the drug approval process. Watch the full webinar here or on our YouTube channel: https://youtu.be/AJzH5a7S6TQ
Lung cancer is responsible for nearly 1 in 5 cancer related deaths in Europe, yet it remains a cancer that is underfunded and underrepresented. Previous research has demonstrated that many people impacted by lung cancer face disparities in access to diagnostics, treatment and care.
To mark World Cancer Day, LuCE has released its latest position paper which identifies disparities and challenges in access to lung cancer diagnostics and treatment across Europe. Data were collected through 34 healthcare professionals/researchers, 16 pharmaceutical companies and LuCE members (patient organizations).
